Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
The University of Texas MD Anderson Cancer Center · The University of Texas Southwestern Medical Center
Abstract
UNLABELLED: Small cell lung cancer (SCLC) is an aggressive malignancy distinct from non-small cell lung cancer (NSCLC) in its metastatic potential and treatment response. Using an integrative proteomic and transcriptomic analysis, we investigated molecular differences contributing to the distinct clinical behavior of SCLCs and NSCLCs. SCLCs showed lower levels of several receptor tyrosine kinases and decreased activation of phosphoinositide 3-kinase (PI3K) and Ras/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK) pathways but significantly increased levels of E2F1-regulated factors including enhancer of zeste homolog 2 (EZH2), thymidylate synthase, apoptosis mediators,…
Citation impact
- FWCI
- 12.46
- Percentile
- 100%
- References
- 45
Authors
28- LALauren A. ByersCorresponding
The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center
- JWJing Wang
The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center
- MBMonique B. Nilsson
The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center
- JFJunya Fujimoto
The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center
- PSPierre Saintigny
The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center
Topics & keywords
- PARP1
- Biology
- Cancer research
- PI3K/AKT/mTOR pathway
- E2F1
- Kinase
- Signal transduction
- Cancer
- Good health and well-being